Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
Cymabay Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 26, 2022
Cymabay Therapeutics reported fiscal year 2021 executive compensation information on April 26, 2022.
In 2021, five executives at Cymabay Therapeutics received on average a compensation package of $1.5M, a 44% decrease compared to previous year.
Average pay of disclosed executives at Cymabay Therapeutics
Sujal Shah, Chief Executive Officer, received $2.2M in total, which decreased by 16% compared to 2020. 61% of Shah's compensation, or $1.3M, was in option awards. Shah also received $320K in non-equity incentive plan, $550K in salary, as well as $3.8K in other compensation.
Dennis Kim, Chief Medical Officer, received a compensation package of $1.8M. 78% of the compensation package, or $1.4M, was in option awards.
Lewis Stuart, Chief Commercial Officer, earned $1.5M in 2021.
Charles A. McWherter, President of R&D, received $1.1M in 2021.
Paul Quinlan, General Counsel, earned $656K in 2021.
Related executives
You may also like
Source: SEC filing on April 26, 2022.